189 related articles for article (PubMed ID: 31287722)
1. Ruthenium dendrimers against acute promyelocytic leukemia:
Michlewska S; Ionov M; Maroto-Díaz M; Szwed A; Ihnatsyeu-Kachan A; Abashkin V; Dzmitruk V; Rogalska A; Denel M; Gapinska M; Shcharbin D; Gomez Ramirez R; de la Mata FJ; Bryszewska M
Future Med Chem; 2019 Jul; 11(14):1741-1756. PubMed ID: 31287722
[TBL] [Abstract][Full Text] [Related]
2. Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer.
Sanz Del Olmo N; Bajo AM; Ionov M; García-Gallego S; Bryszewska M; Gómez R; Ortega P; de la Mata FJ
Eur J Med Chem; 2020 Aug; 199():112414. PubMed ID: 32438200
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium Dendrimers against Human Lymphoblastic Leukemia 1301 Cells.
Michlewska S; Ionov M; Szwed A; Rogalska A; Sanz Del Olmo N; Ortega P; Denel M; Jacenik D; Shcharbin D; de la Mata FJ; Bryszewska M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32526993
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium dendrimers as carriers for anticancer siRNA.
Michlewska S; Ionov M; Maroto-Díaz M; Szwed A; Ihnatsyeu-Kachan A; Loznikova S; Shcharbin D; Maly M; Ramirez RG; de la Mata FJ; Bryszewska M
J Inorg Biochem; 2018 Apr; 181():18-27. PubMed ID: 29353086
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of cytotoxicity by combining pyrenyl-dendrimers and arene ruthenium metallacages.
Pitto-Barry A; Zava O; Dyson PJ; Deschenaux R; Therrien B
Inorg Chem; 2012 Jul; 51(13):7119-24. PubMed ID: 22716166
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.
Michlewska S; Kubczak M; Maroto-Díaz M; Sanz Del Olmo N; Ortega P; Shcharbin D; Gomez Ramirez R; Javier de la Mata F; Ionov M; Bryszewska M
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450702
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.
Maroto-Díaz M; Elie BT; Gómez-Sal P; Pérez-Serrano J; Gómez R; Contel M; Javier de la Mata F
Dalton Trans; 2016 Apr; 45(16):7049-66. PubMed ID: 26990859
[TBL] [Abstract][Full Text] [Related]
8. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
9. Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNA.
Rodríguez-Prieto T; Michlewska S; Hołota M; Ionov M; de la Mata FJ; Cano J; Bryszewska M; Gómez R
J Inorg Biochem; 2021 Oct; 223():111540. PubMed ID: 34273717
[TBL] [Abstract][Full Text] [Related]
10. Dinuclear Organoruthenium Complexes Exhibiting Antiproliferative Activity through DNA Damage and a Reactive-Oxygen-Species-Mediated Endoplasmic Reticulum Stress Pathway.
Zhao J; Li S; Wang X; Xu G; Gou S
Inorg Chem; 2019 Feb; 58(3):2208-2217. PubMed ID: 30675781
[TBL] [Abstract][Full Text] [Related]
11. Double targeting of tumours with pyrenyl-modified dendrimers encapsulated in an arene-ruthenium metallaprism.
Pitto-Barry A; Barry NP; Zava O; Deschenaux R; Dyson PJ; Therrien B
Chemistry; 2011 Feb; 17(6):1966-71. PubMed ID: 21274948
[TBL] [Abstract][Full Text] [Related]
12. Solvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release.
Jayanthi E; Kalaiselvi S; Padma VV; Bhuvanesh NS; Dharmaraj N
Dalton Trans; 2016 Jan; 45(4):1693-707. PubMed ID: 26699435
[TBL] [Abstract][Full Text] [Related]
13. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
14. Novel ruthenium azo-quinoline complexes with enhanced photonuclease activity in human cancer cells.
Kaulage MH; Maji B; Pasadi S; Bhattacharya S; Muniyappa K
Eur J Med Chem; 2017 Oct; 139():1016-1029. PubMed ID: 28910739
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anticancer properties of ruthenium (II) complexes as potent apoptosis inducers through mitochondrial disruption.
Wan D; Tang B; Wang YJ; Guo BH; Yin H; Yi QY; Liu YJ
Eur J Med Chem; 2017 Oct; 139():180-190. PubMed ID: 28800456
[TBL] [Abstract][Full Text] [Related]
16. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Palepu NR; Nongbri SL; Premkumar JR; Verma AK; Bhattacharjee K; Joshi SR; Forbes S; Mozharivskyj Y; Thounaojam R; Aguan K; Kollipara MR
J Biol Inorg Chem; 2015 Jun; 20(4):619-38. PubMed ID: 25712889
[TBL] [Abstract][Full Text] [Related]
18. Organometallic ruthenium(II)-arene complexes with triphenylphosphine amino acid bioconjugates: Synthesis, characterization and biological properties.
Pernar M; Kokan Z; Kralj J; Glasovac Z; Tumir LM; Piantanida I; Eljuga D; Turel I; Brozovic A; Kirin SI
Bioorg Chem; 2019 Jun; 87():432-446. PubMed ID: 30925428
[TBL] [Abstract][Full Text] [Related]
19. New half-sandwich ruthenium(ii) complexes as proteosynthesis inhibitors in cancer cells.
Ballester FJ; Ortega E; Porto V; Kostrhunova H; Davila-Ferreira N; Bautista D; Brabec V; Domínguez F; Santana MD; Ruiz J
Chem Commun (Camb); 2019 Jan; 55(8):1140-1143. PubMed ID: 30631876
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy of ruthenium dendrimers and anti-cancer drugs against human leukemic cells.
Michlewska S; Maroto M; Hołota M; Kubczak M; Sanz Del Olmo N; Ortega P; Shcharbin D; de la Mata FJ; Bryszewska M; Ionov M
Dalton Trans; 2021 Jul; 50(27):9500-9511. PubMed ID: 34254615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
